Griscelli Syndrome Type 1: a novel MYO5A pathogenic variant and characterization of patient-derived fibroblasts
This study reports two Brazilian siblings with Griscelli Syndrome Type 1 caused by a novel homozygous MYO5A pathogenic variant, characterizing the oldest known patient with the condition and establishing a patient-derived fibroblast model that reveals undetectable myosin-Va protein alongside upregulated myosin-Vb and Vc, suggesting potential compensatory mechanisms.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Human bodies are intricate machines built from countless tiny parts working in concert. Among these parts are specialized cells called melanocytes, which produce the pigment that gives skin and hair their color. In a healthy person, these cells act like efficient couriers, packaging pigment into small containers and shipping them out to neighboring skin cells to create an even, natural tone. Sometimes, however, the machinery that moves these packages breaks down. When this happens, the pigment gets stuck inside the cell, unable to reach its destination. This failure leads to a rare condition where a person's hair appears a striking silvery-gray and their skin is unusually pale. While this visual change is the most obvious sign, the underlying cause can also disrupt the nervous system, leading to severe developmental challenges. Understanding exactly how this transport system fails is crucial, not only for diagnosing the condition but for finding ways to help those living with it.
Researchers in Brazil recently turned their attention to a family with two siblings who presented with these exact symptoms. The older sibling, a man now in his late twenties, and his younger sister, who passed away at age twelve, both suffered from profound neurological issues alongside their distinctive silvery hair. Unlike other similar conditions that primarily affect the immune system, these patients showed no signs of immune weakness, pointing scientists toward a specific genetic cause known as Griscelli syndrome type 1. This form of the disease is driven by a defect in a gene called MYO5A, which provides the instructions for building a molecular motor protein. This protein acts as a truck on a cellular highway, carrying the pigment containers along tracks made of actin fibers. Without a working motor, the cargo piles up inside the cell, and the brain, which relies heavily on this same transport system for its own internal logistics, struggles to function correctly.
The team, led by scientists at the University of São Paulo, began by examining the physical evidence. They looked at hair strands under a microscope and found large, irregular clumps of pigment scattered along the shaft, a stark contrast to the smooth, even distribution seen in healthy hair. They also took small samples of skin from the older brother and a healthy volunteer. Under high-powered lenses, the skin cells from the patient revealed a clear problem: the pigment containers were crowded together near the center of the cell, trapped and unable to move outward. This confirmed that the cellular transport system was indeed jammed. To find the root cause, the researchers analyzed the DNA of the siblings and their parents. They discovered that both children had inherited a specific error in the MYO5A gene from each parent. This error was a single letter change in the genetic code that acted as a premature stop sign. Instead of building a full-length, functional motor protein, the cell's machinery stopped halfway through, resulting in a broken, non-existent protein. This specific mutation had never been seen before in medical records.
To understand what happens inside the cells when this motor is missing, the scientists grew skin cells from the patient in a laboratory dish. When they tested these cells, they found no trace of the motor protein, confirming that the genetic error had successfully halted its production. However, the story did not end there. The researchers noticed that the cells had started producing higher levels of two other, similar motor proteins, known as myosin-Vb and myosin-Vc. It appears that when the primary motor fails, the cell attempts to compensate by boosting the production of its backup systems. This finding is significant because it might explain why the older brother survived into his late twenties, a rarity for this condition, as these backup motors may have provided some level of support to his nervous system. The study also ruled out other potential genetic causes, confirming that this specific mutation was the sole driver of the disease in this family.
The researchers now have a unique tool for future study: a living line of cells from the patient that carries this specific genetic error. These cells serve as a model that scientists can use to test new ideas about how the disease works and to explore whether correcting the genetic error could restore function. While there is currently no cure for this form of the syndrome, and treatment focuses on managing symptoms, the discovery of this new mutation and the creation of this cellular model offer a clearer path forward. By understanding exactly how the transport system fails and how the body tries to adapt, researchers can better design therapies that might one day help patients with this devastating condition. The work highlights the resilience of the human body, which tries to find workarounds even when a critical piece of its machinery is broken, and provides a concrete foundation for future medical advances.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.